CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Inclusion Criteria

• •1. The subject voluntarily participates in the clinical study; Fully understand and be Informed of the study and sign the Informed consent (Informed Consent Form, ICF)（For minors, the guardian shall also provide written informed consent ）; Willing to follow and able to complete all test procedures; Informed consent must be obtained before initiating any tests or procedures related to the study that are not part of the standard treatment of the subject's disease;
• •2. Age 14-60 years;
• •3. ECOG score: ≤2;
• •4. Relapsed/refractory AML must meet one of the following conditions:
• •1. Twice or more relapse;
• •2. Newly diagnosed AML patients who failed after 2 cycles of standard chemotherapy;
• •3. Relapse within 12 months after CR, or relapse after 12 months with CR but failed to respond to conventional chemotherapy;
• •4. Persistent extramedullary leukemia.
• •5. Meet the requirements of allogeneic HSCT
• •6. Expected survival ≥ 3 months;